FIXED‐DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PFS AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES. (12th June 2019) - Fischer, K.; Porro Lurà, M.; Al‐Sawaf, O.; Bahlo, J.; Fink, A.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; Liberati, A.M.; et al.